Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| ATG002 (study drug)NCT00316537 | CoMentisPHASE1, PHASE2 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-09 |
| TolterodineNCT00439192 | elbion AGPHASE2 | TERMINATED side effect profile did not match expectations | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-08-08 |
| ELB245NCT00439192 | elbion AGPHASE2 | TERMINATED side effect profile did not match expectations | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-08-08 |
| ADH -1 (Exherin™)NCT00225550 | Adherex Technologies, Inc.PHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-08-06 |
| STI571 and PEG INTRONNCT00511121 | University of BolognaPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-03 |
| CORvalen (D-Ribose)NCT00329485 | Valen LabsNA | TERMINATED Poor recruitment and through put | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-08-02 |
| perflutren lipid microsphereNCT00507806 | ImaRx TherapeuticsPHASE1, PHASE2 | TERMINATED for administrative reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-07-27 |
| Irinotecan, CapecitabineNCT00506168 | National Cancer Center, KoreaPHASE2 | TERMINATED The study drugs are not covered anymore by insurance. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-25 |
| PPI-2458NCT00100347 | PRAECIS Pharmaceuticals Inc.PHASE1 | TERMINATED terminated due to corporate transaction. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-25 |
| UK-500,001NCT00263874 | PfizerPHASE2 | TERMINATED The decision to terminate was completely related to efficacy and there were no safety concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-07-23 |
| eptifibatideNCT00289601 | Brigham and Women's HospitalPHASE4 | TERMINATED Sponsor support withdrawn | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-07-20 |
| CisplatinNCT00195078 | Weill Medical College of Cornell UniversityPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-20 |
| ZD1839 (IRESSA)NCT00195078 | Weill Medical College of Cornell UniversityPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-20 |
| ertapenemNCT00392028 | HaEmek Medical Center, IsraelNA | WITHDRAWN no recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-13 |
| Transtec (R) PRO (buprenorphine)NCT00388219 | Grünenthal GmbHPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-06 |
| iron (2 mg/kg/daily)NCT00497471 | Hospital Clinic of BarcelonaNA | TERMINATED Follow-up end in 1999 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-07-06 |
| Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)NCT00497471 | Hospital Clinic of BarcelonaNA | TERMINATED Follow-up end in 1999 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-07-06 |
| Growth HormoneNCT00397319 | Vanderbilt UniversityPhase unknown | TERMINATED Inadequate retention of GHD adults to maintain power to study the effect of GH on fibrinolysis. A comparison between GHD adults and controls was completed. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-07-03 |
| intravenous (IV) ganciclovirNCT00264368 | University of Oslo School of PharmacyPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-28 |
| Galactose, intravenousNCT00427986 | Glostrup University Hospital, CopenhagenNA | TERMINATED No sufficient increase in plasma osmolarity by galactose (one patient included) | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-26 |
| DetemirNCT00490893 | University Hospital TuebingenPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-25 |
| Eflornithine plus Nifurtimox combination therapyNCT00489658 | EpicentrePHASE2, PHASE3 | TERMINATED Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-21 |
| Anecortave AcetateNCT00211367 | Manhattan Eye, Ear & Throat HospitalPHASE2 | TERMINATED poor enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-21 |
| MEDI-507NCT00105313 | MedImmune LLCPHASE1 | TERMINATED After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-14 |
| MEDI-507NCT00123942 | MedImmune LLCPHASE1 | TERMINATED After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-14 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |